You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞信窩輪》匯豐急挫港交所13連跌,留意匯豐購21564、港交購28553
阿思達克 03-07 13:26
市場繼續關注息口和東歐戰事對國際銀行股的影響,匯豐(0005)週一曾挫超過7%,低見48元以下,是約兩個月低位。向上觀望重上52元的機會,支持或下移至參考250天線46.5元水平。看好可留意匯豐購21564,行使價55.93元,22年6月到期。或匯豐牛52357,收回價45.18元,行使價44.18元,22年12月到期。相反看淡可留意匯豐沽21844,行使價44.83元,22年5月到期。或匯豐熊52371,收回價53.88元,行使價54.88元,22年12月到期。 友邦保險(1299)曾挫逾6%,低見74.05元的52周低位。看好可留意友邦購12731,行使價87.95元,22年9月到期。或友邦牛67859,收回價70.00元,行使價69.40元,22年4月到期。相反看淡則可留意友邦沽20570,行使價65.95元,22年6月到期。或友邦熊52383,收回價82.88元,行使價83.48元,22年10月到期。或友邦熊64984,收回價88.88元,行使價89.48元,22年10月到期。 中國平安(2318)一度跌逾3%,跌穿56元,是約兩個月低位。看好可留意平安購17449,行使價66.71元,22年4月到期。或平安牛60381,收回價52.55元,行使價51.95元,22年7月到期。相反看淡則可留意平安沽22135,行使價47.95元,22年7月到期。或平安熊52390,收回價62.88元,行使價63.48元,22年10月到期。 港交所(0388)未止跌,曾再跌逾4%至340元的逾年半低位,暫連跌13個交易日,短線觀望能否在330元附近止跌,360元關口或具阻力。看好可留意港交購28553,行使價398.88元,22年9月到期。或港交牛67981,收回價321.88元,行使價319.88元,22年12月到期。相反看淡可留意港交熊52376,收回價378.00元,行使價380.00元,22年10月到期。 藥明生物(2269)曾急瀉11%,低見55.1元。看好反彈可留意藥明購24669,行使價66.88元,22年8月到期。或藥明牛52483,收回價50.88元,行使價48.88元,22年12月到期。相反看淡則可留意藥明熊62356,收回價70.00元,行使價71.50元,22年12月到期。 以上產品資料來源: 彭博資訊及瑞信網站cswarrants.com (本結構性產品並無抵押品) 《瑞信香港認股證及牛熊證銷售主管何啓聰》 免責聲明:筆者爲瑞士信貸(香港)有限公司的代表 ,並身爲證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能爲零。有關恆生指數,恆生中國企業指數或恆生科技指數的免責聲明,請參閱上市文件。有關納斯達克100指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司Credit Suisse Securities (Hong Kong) Limited爲結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account